Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | GRB2 | P62993 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 6/20 | 0.43 |
| ▸ | FAP | Q12884 | 2/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.43 |
| ▸ | NTSR2 | O95665 | 5/20 | 0.43 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.43 |
| ▸ | NPY1R | P25929 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.40 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10701287 | 0.96 | XIAP (0.46) | XIAPGRB2DPP4FAPDPP8 | |
| SCHEMBL29391363 | 0.92 | GRB2 (0.55) | XIAPGRB2DPP4FAPDPP8 | |
| SCHEMBL10653187 | 0.91 | GRB2 (0.43) | XIAPGRB2DPP4FAPDPP8 | |
| SCHEMBL29636207 | 0.91 | GRB2 (0.49) | XIAPGRB2DPP4DPP7NMUR2 | |
| SCHEMBL29978208 | 0.91 | MAPK8 (0.50) | GRB2NTSR2NTSR1SORT1NPY1R | |
| SCHEMBL10653313 | 0.90 | GRB2 (0.43) | XIAPGRB2DPP4FAPDPP8 | |
| SCHEMBL30416412 | 0.89 | GRB2 (0.47) | XIAPGRB2NTSR2NTSR1SORT1 | |
| SCHEMBL9668394 | 0.89 | DPP4 (0.41) | XIAPGRB2DPP4FAPDPP8 | |
| SCHEMBL31058052 | 0.89 | OPRM1 (0.47) | XIAPGRB2NTSR2NTSR1SORT1 | |
| SCHEMBL31256960 | 0.89 | XIAP (0.53) | XIAPGRB2NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740954-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES | AZITRA, INC. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3638369-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES | AZITRA INC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12606610-B2 | Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes | AZITRA INC (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4507716-A1 | METHODS OF PREPARING ALBUMIN PREPARATIONS | CSL Behring LLC (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-118324919-A | Antibodies against human trypsin and uses thereof | 北京智仁美博生物科技有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240218049-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES | AZITRA INC (US) | 2024-07-04 | — | — | US | disclosed |
| WO-2023200908-A1 | METHODS OF PREPARING ALBUMIN PREPARATIONS | CSL BEHRING LLC (US) | 2023-10-19 | — | — | WO | disclosed |
| US-11773154-B2 | Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes | AZITRA INC (US) | 2023-10-03 | — | — | US | disclosed |
| CN-116848251-A | Improved high-efficiency specific human Kunitz inhibitors of plasmin | 加利福尼亚大学董事会 | 2023-10-03 | — | — | CN | disclosed |
| CN-103429256-B | Targeting of coagulation factors to TLT-1 on activated platelets | 诺和诺德保健股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606610-B2 | Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes | CUTA, TMPRSS11D, KLK5 | XIAP 1994/4885GRB2 4117/4885DPP4 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.